GSK (GlaxoSmithKline) has agreed to acquire RAPT Therapeutics for $2.2 billion, gaining global rights to the U.S. company's experimental food allergy drug, ozureprubart, which will be integrated into its respiratory and immunology portfolio.
20 Jan 2026-15:46
20 Jan 2026-15:46
